712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors
Metz, Heather, Brender, Ty, Stevens, Brenda, Winship, Damion, Brevik, Jamie, Comeau, Michael, Childs, Monica, Chang, Jenny, Fan, Li-Qun, Xu, Hengyu, Grey, Jonathan, Adamo, Jeffrey, Setter, Ben, Carrillo, Ray, Smith, Sean, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Regulation and Dynamics of IFN-β Expression Revealed with a Knockin Reporter Mouse
Parekh, Nikhil J, Winship, Damion, Van Dis, Erik, Stetson, Daniel B
Published in The Journal of immunology (1950) (30.10.2024)
Published in The Journal of immunology (1950) (30.10.2024)
Get full text
Journal Article
Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTAC™therapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity
Comeau, Michael R., Brender, Ty, Childs, Monica, Brevik, Jamie, Winship, Damion, Metz, Heather, Chang, Jenny, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Stevens, Brenda, Smith, Sean W., Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist
Metz, Heather, Childs, Monica, Brevik, Jamie, Winship, Damion, Brender, Ty, Comeau, Michael, Moyes, Kara, Chang, Jenny, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Smith, Sean, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Abstract PD4-09: Preclinical studies support the development of SBT6050, an anti-HER2 antibody conjugated to a potent TLR8 agonist, for treatment of moderate and high HER2-expressing tumors that lack pre-existing T cell infiltrate
Odegard, Valerie H, Moyes, Kara, Childs, Monica, Brevik, Jamie, Winship, Damion, Brender, Ty, Metz, Heather, Chang, Jenny R, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Smith, Sean W, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
Abstract 1858: SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells
Comeau, Michael R., Metz, Heather, Stevens, Brenda, Winship, Damion, Brevik, Jamie, Rhodehamel, Marcus, Childs, Monica, Hay, Elsa, Chang, Jenny, Fan, Li-Qun, Xu, Hengyu, Grey, Jonathan, Adamo, Jeffrey, Setter, Ben, Carillo, Ray, Smith, Sean W., Tan, Phil, Dubose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article